The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation

Am J Gastroenterol. 2018 Aug;113(8):1261-1263. doi: 10.1038/s41395-018-0145-1. Epub 2018 Jun 12.

Authors

Quan M Nhu^{1

1

1}, Hellen Chiao¹, Fouad J Moawad¹, Fei Bao¹, Gauree G Konijeti^{1

1}

Affiliation

¹ Division of Gastroenterology & Hepatology, Scripps Clinic, La Jolla, CA, USA. Department of Medicine, Scripps Clinic - Scripps Green Hospital, La Jolla, CA, USA. Scripps Translational Science Institute, The Scripps Research Institute, La Jolla, CA, USA. Department of Pathology, Scripps Clinic - Scripps Green Hospital, La Jolla, CA, USA.

PMID: 29895980
DOI: 10.1038/s41395-018-0145-1

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Crohn Disease / complications
Crohn Disease / drug therapy*
Eosinophilic Esophagitis / complications
Eosinophilic Esophagitis / drug therapy*
Gastrointestinal Agents / administration & dosage
Gastrointestinal Agents / therapeutic use*
Humans
Infliximab / administration & dosage
Infliximab / therapeutic use
Integrins / antagonists & inhibitors*
Male

Substances

Antibodies, Monoclonal, Humanized
Gastrointestinal Agents
Integrins
integrin alpha4beta7
vedolizumab
Infliximab

Grants and funding